Company Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation.
The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes.
The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | David-Alexandre Gros |
Contact Details
Address: 19800 MacArthur Boulevard, Suite 250 Irvine, California 92612 United States | |
| Phone | 949 238 8090 |
| Website | eledon.com |
Stock Details
| Ticker Symbol | ELDN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404281 |
| CUSIP Number | 28617K101 |
| ISIN Number | US28617K1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | Chief Executive Officer and Non Independent Director |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer and Non Independent Director |
| Paul Sean Little | Chief Financial Officer |
| John Herberger | Vice President of Technical Operations |
| Bryan E. Smith J.D. | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 22, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | 8-K | Current Report |
| May 11, 2026 | EFFECT | Notice of Effectiveness |
| May 7, 2026 | UPLOAD | Filing |
| May 1, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |